{"transactions":[{"id":944906,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2026-01-07T20:15:13.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":2858,"price":1.012,"value":2892.296,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (\"RSUs\") on January 1, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024.  On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."}],"balance_after":59086,"source":{"system":"sec-edgar","filing":"0001193125-26-006770","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000119312526006770/ownership.xml","form_type":"4"}},{"id":944905,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2026-01-07T20:15:13.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":3604,"price":1.003,"value":3614.812,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (\"RSUs\") on January 1, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, (b) a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024.  On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026; and (c) 28,000 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."}],"balance_after":61944,"source":{"system":"sec-edgar","filing":"0001193125-26-006770","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000119312526006770/ownership.xml","form_type":"4"}},{"id":1005976,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2025-11-06T18:11:32.000Z","date":"2025-11-04","kind":"sale","planned":false,"acquired":false,"shares":765,"price":1.14,"value":872.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (\"RSUs\") on November 4, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, in accordance with the original terms, (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on September 30, 2025."}],"balance_after":65548,"source":{"system":"sec-edgar","filing":"0001193125-25-270252","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000119312525270252/ownership.xml","form_type":"4"}},{"id":1238890,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-28T16:19:36.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date."}],"balance_after":56000,"derivative":{"exercise_price":1.13,"expiration_date":"2035-02-25","underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0000950170-25-030032","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000095017025030032/ownership.xml","form_type":"4"}},{"id":1238889,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2025-02-28T16:19:36.000Z","date":"2025-02-26","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."}],"balance_after":61313,"source":{"system":"sec-edgar","filing":"0000950170-25-030032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000095017025030032/ownership.xml","form_type":"4"}},{"id":1308454,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2025-01-07T19:57:18.000Z","date":"2025-01-03","kind":"sale","planned":false,"acquired":false,"shares":2029,"price":1.341,"value":2720.889,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (\"RSUs\") on January 1, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (a) 10,125 RSUs which shall vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024 and (b) 12,031 RSUs which shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."}],"balance_after":33313,"source":{"system":"sec-edgar","filing":"0000950170-25-003153","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000095017025003153/ownership.xml","form_type":"4"}},{"id":1375765,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-05T16:57:11.000Z","date":"2024-11-04","kind":"grant","planned":false,"acquired":true,"shares":20250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option are exercisable and vest as follows: 1/48th of the shares vest and becomes exercisable monthly over four years from November 4, 2024 until fully vested and exercisable on November 4, 2028, subject to the Reporting Person's continuous service as of such date."}],"balance_after":20250,"derivative":{"exercise_price":1.08,"expiration_date":"2034-11-03","underlying":"Common Stock","underlying_shares":20250},"source":{"system":"sec-edgar","filing":"0000950170-24-121601","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000095017024121601/ownership.xml","form_type":"4"}},{"id":1375764,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":69859,"kind":"person","name":"Prior Stephen David","position":1,"cik":"0002042268","reported_name":"Prior Stephen David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-11-05T16:57:11.000Z","date":"2024-11-04","kind":"grant","planned":false,"acquired":true,"shares":10125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\"). RSUs vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, subject to the Reporting Person's continuous service as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes a balance of 17,500 RSUs which shall continue to vest as originally approved through December 31, 2024. On January 1, 2025, 1/3 of the remaining RSUs (rounded down to the nearest whole number of shares) shall vest and all remaining unvested RSUs shall vest on January 1, 2026, in each case, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date."}],"balance_after":35342,"source":{"system":"sec-edgar","filing":"0000950170-24-121601","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042268/000095017024121601/ownership.xml","form_type":"4"}}]}